{"doi":"10.20900/mo.20160012","title":"Case Report of First-line Chemotherapy on One Advanced Lung Cancer Patient with Bevacizumab combined with Pemetrexed Disodium and Carboplatin","abstract":null,"journal":"Med One","year":2016,"id":686582,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Case Report of First-line Chemotherapy on One Advanced Lung Cancer Patient with Bevacizumab combined with Pemetrexed Disodium and Carboplatin","abstract":"A single case of a male stage-IV lung cancer patient is reported, there were exon 19 deletion mutations in the epidermal growth factor receptor (EGFR). Intra-, and extrapulmonary, lesions occurred a month after gefitinib and erlotinib applications. Patient was then switched to the first-line chemotherapy program. Both types of lesions significantly improved four weeks after a combined therapy of pemetrexed disodium + carboplatin+ bevacizumab (7.5mg/Kg d1), two weeks after continuous therapy with pemetrexed disodium + bevacizumab (7.5mg/ Kg d1). Short-term efficacy was assessed as PR, without significant adverse effects, reflecting program efficacy and good tolerance.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"26207759","pmcid":null,"openalex_id":"https://openalex.org/W2906748950","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.32672079,"influential_citations":0,"citation_trend":[],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://doi.org/10.20900/mo.20160012","host_type":"journal"},{"url":"https://doi.org/10.20900/mo.20160012","host_type":"publisher"},{"url":"http://mo.qingres.com/UpLoad/PdfFile/mo_803.pdf","host_type":"publisher"},{"url":"https://doaj.org/article/62488098f5bd440c8a8c426a61843a11","host_type":"repository"}],"fields_of_study":["Lung Cancer Treatments and Mutations","Colorectal Cancer Treatments and Studies","Lymphoma Diagnosis and Treatment"],"mesh_terms":[],"keywords":["Pemetrexed","Bevacizumab","Carboplatin","Medicine","Erlotinib","Gefitinib","Lung cancer","Oncology","Internal medicine","Epidermal growth factor receptor","Chemotherapy","Cancer","Cisplatin"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-18T19:55:04.667325Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}